Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Acrokeratosis Neoplastica : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Multimedia
References

Related Articles
Contact Dermatitis, Allergic

Lupus Erythematosus, Acute

Lupus Erythematosus, Subacute Cutaneous

Onycholysis

Onychomycosis




Patient Education
Click here for patient education.



Author: Karen Allen, MD, Consulting Dermatologist

Karen Allen is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology

Editors: Jean-Hilaire Saurat, MD, Chair, Professor, Department of Dermatology, University of Geneva, Switzerland; David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Director, Division of Dermatology, Scott and White Clinic; Director Dermatology Residency Training Program, Scott and White Clinic; Jeffrey Meffert, MD, Assistant Clinical Professor of Dermatology, University of Texas Health Science Center-San Antonio; Catherine Quirk, MD, Clinical Assistant Professor, Department of Dermatology, Brown University; William D James, MD, Paul R Gross Professor of Dermatology, University of Pennsylvania School of Medicine; Vice-Chair, Program Director, Department of Dermatology, University of Pennsylvania Health System

Author and Editor Disclosure

Synonyms and related keywords: Bazex syndrome, paraneoplastic acrokeratosis

Background

Acrokeratosis neoplastica (AN) is a rare psoriasiform dermatosis that is associated consistently with internal malignancy, usually squamous cell carcinoma (SCC) of the upper aerodigestive tract. Skin manifestations include acute onset of onychodystrophy and violaceous scaly patches on the helices, nose, and malar and acral surfaces. Usually, skin manifestations precede diagnosis of the malignancy.

The term Bazex syndrome describes 2 different entities: AN and the genetic syndrome of basal cell carcinomas, follicular atrophoderma, hypotrichosis, and hypohidrosis or hyperhidrosis.

Pathophysiology

The skin manifestations of AN parallel the disease course, suggesting the presence of circulating antibodies to tumor antigens. Cytokines may play a role.

Frequency

United States

Approximately 125 cases have been reported in the literature.

Mortality/Morbidity

  • Mortality and morbidity are related directly to the available treatment options for the underlying neoplasm.
  • In most reported cases, cervical lymph node metastases are present at the time of diagnosis, usually indicating a poor prognosis.

Sex

In one review, 105 of 113 cases were in males.

Age

Mean age of onset is 61 years.



History

  • Skin findings usually begin with scaling dermatosis of the fingers and toes that quickly spreads to the nails (Media File 1).
    • Nails can show severe dystrophy with painful paronychia, subungual debris, and linear striations. In the absence of evidence of fungal infection, acute onset of this dystrophy indicates AN.
    • Involvement of the ear helices with a violaceous scaly eruption is a constant finding.
    • With further progression, involvement of the cheeks and nose occurs.
    • In the second stage of AN, a palmoplantar keratoderma is present that also can be violaceous in color.
    • The final stage may involve similar skin findings extending to the trunk, extremities, and scalp (Media File 2).
    • Although the paronychia of the nails may be painful and tender and cracking and fissuring of the fingertips may be seen, the papulosquamous lesions typically are asymptomatic.
  • On further questioning, patients may admit to mild constitutional symptoms, weight loss, and other nonspecific findings of internal malignancy.

Causes

  • Most AN cases are associated with SCC of the upper one third of the respiratory tract or the GI tract (oral cavity, pharynx, larynx, esophagus).
  • Generally, the lymph nodes already are involved at diagnosis.
  • Case reports also exist of SCC of the thymus and vulva and of poorly differentiated SCC of the cervical lymph nodes with an unknown primary tumor.
  • Rare associated cancers reported include anaplastic small cell carcinoma of the lung and adenocarcinoma of the uterus.



Contact Dermatitis, Allergic
Lupus Erythematosus, Acute
Lupus Erythematosus, Subacute Cutaneous
Onycholysis
Onychomycosis

Other Problems to be Considered

Drug eruption
Photodermatitis



Lab Studies

  • Physical examination may indicate the need for specific laboratory studies in the search for underlying malignancy. Other screening laboratory studies may reveal evidence of GI or renal malignancies.
    • General chemistry panel to evaluate for occult hepatic or renal disease
    • Urinalysis
    • Complete blood cell count
    • Test for occult blood in the stool
  • KOH (negative in AN) to exclude fungal infection, which is in the differential of AN.

Imaging Studies

  • Chest radiography
  • CT scanning or MRI of specific body sites or as part of a general radiologic screening
  • Pelvic ultrasonography
  • Mammography

Other Tests

  • Lymph node biopsy if adenopathy is present
  • Bronchoscopy
  • Upper GI endoscopy
  • Rhinolaryngoscopy

Histologic Findings

Skin biopsy specimens often reveal nonspecific changes of a psoriasiform or spongiotic dermatitis. Some authors have noted vacuolar degeneration of the basal cell layer with occasional bullae formation.



Medical Care

  • Treatment depends on the type and stage of the underlying neoplasm. Often, treating the neoplasm improves the cutaneous disease. If the neoplasm is cured, skin signs abate.
  • While specific treatment of the skin improves the eruption, this usually is not curative.
    • Topical corticosteroids may improve scaly lesions.
    • Therapy with cholecalciferol also has been reported to be of benefit.

Consultations

  • Consultation with an internal medicine specialist for malignancy workup is appropriate.
  • Consultation with a hematologist, oncologist, otolaryngologist and/or gastroenterologist also can assist with focused evaluations.



The goal of pharmacotherapy is to improve scaly lesions, reduce morbidity, and prevent complications.

Drug Category: Corticosteroids

These agents have anti-inflammatory properties and cause profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli.

Drug NameBetamethasone (Diprolene, Betatrex)
DescriptionFor inflammatory dermatosis responsive to steroids. Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing capillary permeability.
Adult DoseApply thin film bid/qid until response
Pediatric DoseAdminister as in adults with caution
ContraindicationsDocumented hypersensitivity; paronychia; cellulitis; impetigo; angular cheilitis; erythrasma; erysipelas; rosacea; perioral dermatitis; and acne
InteractionsNone reported
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsDo not use in skin with decreased circulation; can cause atrophy of groin, face, and axillae; if infection develops and is not responsive to antibiotic treatment, discontinue until infection is under control; do not use monotherapy to treat widespread plaque psoriasis

Drug Category: Dietary Supplements

For treatment of vitamin D deficiency or prophylaxis of vitamin D deficiency. Vitamin D and its analogs have profound effects on cellular proliferation and differentiation in addition to immunomodulatory effects. Calcipotriene, a vitamin D analog, is a well-accepted treatment for psoriasis, which is a condition that shares some similarities with AN. However, the reports of efficacy in the treatment of AN with vitamin D are anecdotal.

Drug NameCholecalciferol (Delta-D, Vitamin D-3)
DescriptionStimulates absorption of calcium and phosphate from small intestine and promotes release of calcium from bone into blood. Antiproliferative and anti-inflammatory effects on skin.
Adult DoseDelta-D: 400 IU PO qd
Vitamin D-3: 1000 IU PO qd
Calcitriol: 0.25-1 mcg PO qd
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; hypercalcemia; malabsorption syndrome
InteractionsColestipol, mineral oil, and cholestyramine may decrease absorption of ergocalciferol from small intestine; thiazide diuretics may increase effects of vitamin D; may interfere with calcium channel blockers
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCaution in impaired renal function, renal stones, heart disease, or arteriosclerosis



Prognosis

  • In most reported cases of AN, cervical lymph node metastases are present at the time of diagnosis, usually indicating a poor prognosis.



Media file 1:  Bazex syndrome. Acquired palmar keratoderma in a woman with a history of breast cancer and recent primary lung cancer. Courtesy of Jeffrey J Meffert, MD.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Photo

Media file 2:  Bazex syndrome. Violaceous psoriasiform dermatitis on the ankles (same patient as in Image 1). Lung cancer appeared to be in remission; both keratoderma and psoriasiform plaques resolved quickly with clobetasol ointment. Courtesy of Jeffrey J Meffert, MD.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  Photo



  • Bolognia JL. Bazex syndrome: acrokeratosis paraneoplastica. Semin Dermatol. Jun 1995;14(2):84-9. [Medline].
  • Boudoulas O, Camisa C. Paraneoplastic acrokeratosis: Bazex syndrome. Cutis. Jun 1986;37(6):449-53. [Medline].
  • Richard M, Giroux JM. Acrokeratosis paraneoplastica (Bazex'' syndrome). J Am Acad Dermatol. Jan 1987;16(1 Pt 2):178-83. [Medline].

Acrokeratosis Neoplastica excerpt

Article Last Updated: Aug 17, 2005